This post hoc analysis of gastrointestinal (GI) adverse events (AEs) from the phase 3 LixiLan-L (NCT02058160) and LixiLan-O (NCT02058147) trials aimed to determine the frequency and timing of nausea, vomiting, and diarrhoea for iGlarLixi, a titratable, fixed-ratio combination of insulin glargine 100 units/mL (iGlar) and lixisenatide, versus iGlar alone or iGlar and lixisenatide alone, in patients with type 2 diabetes uncontrolled with oral antidiabetes drugs (OADs) or basal insulin AE OADs. In iGlarLixi-treated patients, the rate of GI AEs during the initial weeks of treatment was lower versus patients treated with lixisenatide alone (9.6% and 11.7% of iGlarLixitreated patients in LixiLan-L and LixiLan-O, respectively, vs. 27.5% of lixisenatide-treated patients in LixiLan-O). Beyond day 60, these rates were generally low and similar to those of lixisenatide. These lower rates are likely due to the gradual titration of lixisenatide in iGlarLixi.
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Median durations of intermittent GI AEs in the iGlarLixi arms were 6.0, 2.0 and 2.5 days (LixiLan-L), and 5.0, 1.0 and 3.5 days (LixiLan-O), respectively. iGlarLixi-associated GI AEs were transient, mostly mild or moderate in severity, and occurred mainly during initial titration.
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| INTRODUCTION
For many patients with type 2 diabetes, treatment with basal insulin AE oral antidiabetes drugs (OADs) will eventually be insufficient to maintain glycated HbA1c targets, and additional treatment will be required to control residual hyperglycaemia. 1 A recent guideline's recommended approach for intensifying basal insulin is the addition of glucagon-like peptide-1 receptor agonists (GLP-1RAs), 1,2 which act on both fasting plasma glucose (FPG) and postprandial plasma glucose (PPG) by enhancing glucose-dependent insulin secretion and decreasing glucagon secretion while slowing gastric emptying and increasing satiety. 3 Shorter-acting GLP-1RAs show greater reductions in PPG versus longer-acting agents. 3 Coadministration of basal insulin and GLP-1RAs results in equivalent or improved HbA1c levels, weight loss or no weight gain, and decreased or no increased hypoglycaemia risk, compared with basal insulin alone [4] [5] [6] [7] [8] [9] or in combination with rapid-acting insulins (basal-plus and basal-bolus). [10] [11] [12] However, gastrointestinal (GI) adverse events (AEs) are common side effects of GLP-1RAs. 1, 2 iGlarLixi (SOLIQUA 100/33), a titratable, fixed-ratio combination of insulin glargine 100 units/mL (iGlar) and GLP-1RA lixisenatide 33 μg/mL, is indicated in the USA as a once-daily injection for patients with type 2 diabetes inadequately controlled with basal insulin (<60 units/day) or lixisenatide. 13 In the LixiLan phase 3 trials, iGlarLixi led to greater reductions in HbA1c than either iGlar or lixisenatide alone, with the benefit of weight loss or neutrality, and without increased risk of hypoglycaemia versus iGlar alone. iGlarLixi was associated with low rates of nausea, vomiting, and diarrhoea compared with lixisenatide alone, but with higher rates of these events compared with iGlar alone. 5, 6 Discontinuation rates due to GI AEs associated with iGlarLixi were very low (<1.5%), and fewer patients receiving iGlarLixi in LixiLan-O withdrew versus those receiving lixisenatide alone. No patients treated with iGlar discontinued treatment due to GI AEs in either trial. 5, 6 GI AEs associated with iGlarLixi and lixisenatide appeared to subside over time in the LixiLan trials. This post hoc analysis aimed to assess the frequency and timing of GI AEs in these trials evaluating iGlarLixi in patients with type 2 diabetes.
| MATERIALS AND METHODS

| Study design
This was a post hoc analysis of data from two open-label, randomized, parallel-group, multinational, multicentre phase 3 clinical trials. 5, 6 LixiLan-L (NCT02058160) compared iGlarLixi (n = 367) with iGlar doses were titrated and capped as described for LixiLan-L. iGlarLixi was administered within 60 min before breakfast, iGlar at any time of the day but at roughly the same time each day, and lixisenatide within 60 min before breakfast or dinner. Ten μg of lixisenatide was administered during the first 2 weeks, rising to 20 μg over 30 weeks. 5 In both trials, the safety population included all randomized patients who received at least one dose of iGlarLixi, iGlar or lixisenatide.
5,6
| Statistical analysis
The incidence, timing, and duration of selected GI AEs (nausea, vomiting and diarrhoea) arising from the start to the end of the trials (~210 days)
were evaluated. Results were summarized by treatment group using descriptive statistics. P values were calculated from a two-sample t-test comparing patients who did and did not experience GI AEs.
The severity of the GI AEs was determined by the investigators. 3 | RESULTS
| Baseline patient characteristics
All patients in the safety population were included in the analysis:
736 patients from LixiLan-L and 1170 patients from LixiLan-O. No significant differences in age, HbA1c levels, body mass index or disease duration were seen between patients experiencing GI AEs versus those not reporting GI AEs in both trials (see the supporting information for this article, Table S1 in File S1).
| Incidence of GI AEs over time
The number of patients with a first complaint of nausea, vomiting or diarrhoea peaked within the first 60 days (8 weeks) and subsequently decreased over time in the iGlarLixi and lixisenatide groups (Figure 1 ).
In LixiLan-L, the incidences of nausea and vomiting were low throughout the trial for iGlarLixi, and almost null for the iGlar arm ( Figure 1A ).
Nausea and vomiting were marked during the initial weeks of treatment with lixisenatide in LixiLan-O ( Figure 1B ).
| Severity of GI AEs
Most GI AEs in the LixiLan trials were mild to moderate in severity for all treatment groups (Figure 2 ). In the group of iGlarLixi-treated patients 
| Duration of GI AEs
Median durations of nausea and vomiting were lower with iGlarLixi versus lixisenatide in LixiLan-O, while the shortest durations of GI AEs were seen with iGlar treatment in both trials (Table S2 in File S1).
| Daily doses of iGlar and lixisenatide
The mean daily doses of iGlar and lixisenatide administered as part of the combination, as well as iGlar administered individually, increased throughout the trials. There were no statistically significant differences in daily iGlar doses between patients experiencing GI AEs versus those not reporting them in the iGlarLixi and the iGlar arms in either of the trials (Table S3 in File S1). Treatment with iGlarLixi has been shown to achieve significantly greater reductions in HbA1c levels than iGlar alone. 5, 6 Although adherence to medication is a major determinant of glycaemic control in type 2 diabetes, 16, 17 real-world data show that approximately 35% of patients discontinue treatment with GLP-1RAs after 6 months. 18 Additionally, non-iGlarLixi/lixisenatide-related events that could potentially cause GI AEs were not captured in this analysis. It must also be taken into consideration that the LixiLan studies evaluated different patient populations with distinct baseline characteristics.
| DISCUSSION
In summary, patients with type 2 diabetes treated with iGlarLixi in the LixiLan trials showed low rates of GI AEs versus lixisenatide alone.
GI AEs associated with iGlarLixi tended to be transient and mild/moderate in severity; the majority occurred early in the course of treatment, with most patients no longer experiencing them beyond 8 weeks. iGlarLixi thus offers an alternative to treatment progression for patients not at target after lifestyle changes and treatment with oral agents by adding a GLP-1RA or basal insulin alone. Titration of iGlarLixi is similar to basal insulin titration and shows greater potential to achieve glycaemic targets with fewer GI AEs than either a GLP-1RA alone or a GLP-1RA plus basal insulin as a free combination.
ACKNOWLEDGMENTS
The authors received writing/editorial support in the preparation of this manuscript provided by Patricia Fonseca, PhD, of Excerpta Medica, funded by Sanofi US, Inc. We thank Yan Yan of TechData Service
Company, LLC for assisting with the statistical analysis.
